Business
Endonovo Targets Dept. of Defense, VA & Federal Contracts
Endonovo Targets Dept. of Defense, VA & Federal Contracts.
About this update from Endonovo Therapeutics, Inc.
[{"type":"text","content":"\n Los Angeles, CA, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) announced the advancement of its aggressive “Go to Market” strategy for expansion of SofPulse® medical device distribution through the U.S. Department of Defense (DoD), Veterans Administration (VA) and other federal healthcare facilities (FHS) contracts. President and Chief Commercial Officer of Endonovo’s Medical Division, Ira Weisberg, is overseeing the “Go to Market” strategy and is actively engaging in contract talks geared toward expanding sales and marketing efforts for licensing and distribution contracts of SofPulse® through the government channels. The VA and DoD are responsible for providing healthcare and other services to members of the military and veteran populations in the United States. Both the VA and DoD have established systems for purchasing goods and services, which may include specific requirements for contractors, such as registered Small Business Administration (SBA) firms or Service-Disabled Veteran-Owned Small Business (SDVOSB) firms. Weisberg Leads Negotiations. In making the announcement, Weisberg commented: “We are actively negotiating with a veteran-owned company that will provide for the introduction of SofPulse® into the Department of Defense, Veterans Administration and other federal healthcare facilities. Providing SofPulse®, an FDA cleared medical device, designed to provide a viable alternative to opioid pain management for surgical patients to all our DoD and VA physicians, hospitals and patients offers a pain management solution that has shown to provide patients with improved post-surgical outcomes. Weisberg continued: “Endonovo is expanding our mission to become a prime supplier into the federal supply system and extending the benefits of SofPulse®. We are presently engaged in talks with a world-class government and academic collaboration to bring sensible pain management methods to the military.” “NewCo” Spin-Off to Focus on SofPulse® Endonovo is presently expanding sales and marketing efforts in support of its “Go to Market” strategy with the belief that new management and sales efforts can take the previously announced spin-off, NewCo, focused on SofPulse® medical devices and IP to gener...